Historical record - last NADAC effective date: 12/21/2022
Product Information
POTASSIUM CL ER 8 MEQ CAPSULE is a generic product labeled by Adare Pharmaceuticals Inc, priced at $0.1333 per EA under NDC 59917010201. Its NADAC has been published 244 times since Apr 25, 2018.
FDA first approved this application on Mar 17, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
600 mg/1
Manufacturer
Adare Pharmaceuticals IncNDC
59917010201
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
12/21/2022
Active Ingredients
POTASSIUM CHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA208864FDA Approved
3/17/2017
TE Code
AB
On Market Since
4/1/2018
Pharmacological Classes
Price Statistics
The NADAC for POTASSIUM CL ER 8 MEQ CAPSULE has been published 244 times since Apr 25, 2018, and over the history we have for it it has declined 58.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1333 per EA |
|---|---|
| All-time high | $0.4054 (Apr 10, 2019) |
| All-time low | $0.1169 (Nov 23, 2022) |
| Median price | $0.2686 |
| Average price | $0.2684 |
| Largest weekly change | -44.0% (Nov 23, 2022) |
| Weeks tracked | 244 |
| Tracking since | Apr 25, 2018 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
-26.1%
All
-58.4%
Last surveyed Dec 21, 2022 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 25% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Adare Pharmaceuticals Inc manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
POTASSIUM CHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Osmotic Laxative class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of POTASSIUM CL ER 8 MEQ CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for POTASSIUM CL ER 8 MEQ CAPSULE, manufactured by Adare Pharmaceuticals Inc, is $0.1333 per EA (NDC 59917010201), effective Dec 21, 2022.
How has the price of POTASSIUM CL ER 8 MEQ CAPSULE changed over time?
Over the history we have for it, the NADAC for POTASSIUM CL ER 8 MEQ CAPSULE has declined 58.4%. It has been tracked across 244 weekly CMS publications since Apr 25, 2018.
What are the highest and lowest recorded NADAC prices for POTASSIUM CL ER 8 MEQ CAPSULE?
Since Apr 25, 2018, the NADAC for POTASSIUM CL ER 8 MEQ CAPSULE has ranged from a low of $0.1169 (Nov 23, 2022) to a high of $0.4054 (Apr 10, 2019), with a median of $0.2686 per EA.
Are there cheaper alternatives to POTASSIUM CL ER 8 MEQ CAPSULE?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, POTASSIUM CL ER 8 MEQ CAPSULE, is $0.0998 per EA — about 25% below POTASSIUM CL ER 8 MEQ CAPSULE.
Who manufactures POTASSIUM CL ER 8 MEQ CAPSULE?
POTASSIUM CL ER 8 MEQ CAPSULE (NDC 59917010201) is labeled by Adare Pharmaceuticals Inc, and CMS classifies it as a generic product.